Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders

The remarkably high and growing placebo response rates in clinical trials for CNS indications, such as depression and schizophrenia, constitute a major challenge for the drug development enterprise. Despite extensive literature on participant expectancies and other potent psychosocial factors that p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Elan A., Hassman, Howard H., Ereshefsky, Larry, Walling, David P., Grindell, Vera M., Keefe, Richard S. E., Wyka, Katarzyna, Horan, William P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026614/
https://www.ncbi.nlm.nih.gov/pubmed/33244149
http://dx.doi.org/10.1038/s41386-020-00911-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026614/
https://www.ncbi.nlm.nih.gov/pubmed/33244149
http://dx.doi.org/10.1038/s41386-020-00911-5

Ejemplares similares